Moderna to report oncology vaccine data and Phase 3 results Oct. 24
Moderna will present Phase 3 and full cancer vaccine results with Merck on Oct. 24 in Madrid, amid management changes and market scrutiny.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
TradingView reports that Moderna, Inc. (NASDAQ:MRNA) will present Phase 3 results for its personalized neoantigen cancer therapy, intismeran autogene, on October 24. Moderna and Merck are also scheduled to release full data from their cancer vaccine program that day at a major conference in Madrid.
The company has named Juan Andres as chief operating officer as it expands its oncology programs and commercial vaccine efforts. According to TradingView, Moderna shares were trading above $200 while some analysts adjusted their models.
Citi downgraded Moderna to Sell. Analyst Geoff Meacham set an $80 target, pointing to valuation concerns and the company’s market capitalization approaching Regeneron’s despite lower expected revenue and earnings. Moderna also attracted premarket buying ahead of its inclusion in the Nasdaq-100 the following day, as some index funds may have purchased shares in advance. TradingView says the item was generated by AI and may contain inaccuracies.
why it matters
The October 24 disclosures are the main near-term catalyst described in the report, while Nasdaq-100 inclusion could affect demand from index-tracking funds. Citi’s call also highlights disagreement over Moderna’s valuation and earnings outlook.
instruments
sources
- Weekly Recap: Phase 3 intismeran autogene and Merck Madrid vaccine results — TradingView, 12 October 2026 at 11:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗